are derived ranged from those groups that achieve the lowest bleed this allows a profile of what the chemical compound for a potential anti bleed agent should look like in order to have a high probability of significantly reducing bleed as shown in fig8 which plots bleed normalized to monomer results vs number of matches to low bleed profile experimental results have verified that the lowest bleed occurs when the anti bleed agent candidates have the greatest number of matches to the ranges predicted in fig1 to 7 for overall low bleed this contrasts model au substrate results and experimental expt results also fig9 demonstrates the low experimental bleed corresponding to a low risk factor where the risk of significant bleed is calculated from the modeled bleed and the number of deficiencies to the low bleed profile these risk factors are also useful in predicting the bleed performance of formulations which are too complicated to model explicitly or where an extrapolation is required from elements of previous models although the experimental formulations cannot be modeled explicitly due to unknown and proprietary components the effect of the anti bleed agent may be estimated using averaged results of known modeled components the bleed performance can be predicted for such formulations from an average risk factor which is derived from the particular compounds incorporated in the formulation fig1 uses an average risk to estimate the relative performance risk of the two formulations tested benzylidene malonitrile cis and trans dimethyloctadienitrile and cis and trans citronitrile have experimentally performed well as anti bleed agents these.